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Autism spectrum disorders (ASD) are common, heritable neurodevelopmental conditions. 
The genetic architecture of ASD is complex, requiring large samples to overcome 
heterogeneity. Here we broaden coverage and sample size relative to other studies of ASD by 
using Affymetrix 10K single nucleotide polymorphism (SNP) arrays and 1168 families with 
≥ 2 affected individuals to perform the largest linkage scan to date, while also analyzing copy 
number variation (CNV) in these families. Linkage and CNV analyses implicate 
chromosome 11p12-p13 and neurexins, respectively, amongst other candidate loci. 
Neurexins team with previously-implicated neuroligins for glutamatergic synaptogenesis, 
highlighting glutamate-related genes as promising candidates for ASD. 
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Autism is a neurodevelopmental disorder characterized by impairments in reciprocal social 
interaction, communication deficits and repetitive and restricted patterns of behavior and interests. 
Autistic disorder is the prototypical Pervasive Developmental Disorder (PDD=ASD), which form 
a group that also includes Asperger’s disorder, PDD-not otherwise specified, and Rett disorder1. 
Population prevalence of autism is approximately 15-20 in 10,000, while all ASDs affect about 60 
in 10,000 children. Occurring worldwide, males are affected fourfold more than females2. In only 
about 10% of individuals is autism associated with a recognized cause, most commonly fragile X 
syndrome, tuberous sclerosis and chromosomal abnormalities3,4.  
 Twin studies show concordance of 60-92% for monozygotic twins and 0-10% for dizygotic 
pairs, depending on phenotypic definitions5. Milder phenotypes are similarly elevated in relatives 
of singleton probands, consistent with a spectrum of severity6. The estimated prevalence of autism 
in siblings is 5-10%7,8. The ratio of sibling recurrence risk to population prevalence varies from 67 
to 25, both larger than most multifactorial diseases. While familial clustering in autism could 
reflect shared environmental factors, twin studies5,9 and the distribution of milder phenotypes in 
families favors a model involving multiple interacting loci10,11. We hypothesize that liability to 
autism is due, in large part, to oligogenic inheritance in which combinations of susceptibility 
alleles contribute. Variation in phenotypic severity of sibling pairs and family members 
ascertained through an autistic proband are both consistent with this hypothesis. Based on 
numerous observations of karyotypic abnormalities in autism, we also hypothesize that 
submicroscopic alterations are involved.  
Genome-wide linkage scans (12 and reviewed in ref 13) for autism susceptibility loci have 
identified chromosomal regions 2q, 7q and 17q, with 7q yielding the most positive results, 
including support from meta-analysis. Moreover, substantial evidence suggests that chromosomal 
abnormalities contribute to autism risk, but the exact prevalence is unclear because literature 
surveys span different diagnostic and cytogenetic approaches and sample sizes. Recent surveys3,4 
show a mean rate of gross mutations and chromosomal abnormalities between 4.3% (78/1826) and 
7.4% (129/1749), but many studies find rates of detected abnormalities per individual of 5-10%3. 
Among the most frequent findings are fra(X)(q27)(3.1%; 28/899) and anomalies involving 
proximal 15q (0.97%; 17/1749), specifically the Prader-Willi and Angelman region3,4. 
Duplications of 15q11-q13, typically of maternal origin, are observed in 1-3% of cases, either as 
interstitial duplications or supernumerary isodicentric marker chromosomes containing one or two 
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extra copies of this region3. Linkage, association, and/or chromosome rearrangement studies have 
identified several ASD candidates including genes encoding neuroligins and their binding partners 
as having disease-associated mutations14-17. 
In our model for autism, combinations of multiple, possibly-interacting loci and microscopic or 
sub-microscopic chromosomal abnormalities contribute to risk complicating the detection of 
individual loci. Increasing the likelihood of detecting loci requires analyzing a large sample of 
multiplex (≥ 2 affected individuals) families, thereby enhancing the power of linkage analysis; and 
controlling sources of etiologic heterogeneity (herein, the term families implies multiplex 
families).  
We have assembled a sample of over 1400 ASD families, a resource sufficiently large to 
implement multiple strategies for localizing susceptibility loci (see “Power” in Supplementary 
Methods.) While some linkage studies have attempted to control heterogeneity attributable to 
chromosomal abnormalities by excluding the small number of affected families, none have 
attempted to merge linkage analysis with studies of fine-level chromosomal variation. We develop 
an approach, using comparative analysis of hybridization intensities to identify submicroscopic 
copy number variation (CNV) as putative risk loci, and also as a tool to stratify the sample to 
reduce genetic heterogeneity for linkage analyses.  
 
RESULTS 
ASD samples 
The Autism Genome Project (AGP) Consortium, comprised of scientists from 50 centres in North 
America and Europe, collected 1,496 ASD families (7,917 family members) for this study. 
Diagnosis was based on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism 
Diagnostic Observation Schedule (ADOS) or clinical evaluation (see ref 18 and Methods). Sample 
origins are shown in Supplementary Methods; most samples were karyotyped (≈71%) and 
screened for fragile X mutations (≈94%) and families were excluded if either was abnormal in at 
least one affected individual. Most cell lines or DNA arising from the project are available at the 
NIMH Center for Collaborative Genetic Studies, the European Collection of Cell Cultures, and the 
Autism Genetics Research Exchange. We genotyped genomic or in some cases whole genome 
amplified (WGA) DNA.  
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Linkage analysis by diagnostic group 
We successfully generated genotypes from 1,491 of 1,496 nominal families (6,709 samples; Table 
1) using the Affymetrix 10K v2 SNP array. WGA had no discernible impact on genotyping 
accuracy: for 12 duplicate samples assessed, concordance of genotypes for WGA versus blood 
DNA was >99.6% with no significant difference in completion rates (both ≈ 94%). From the 
10,112 SNPs initially genotyped, quality control (QC) procedures resulted in marker exclusion for 
the following reasons: minor allele frequency < 0.05 (-749 SNPs); high rate of missing genotypes 
(-1,112 SNPs); selection of tag SNPs (-1,734 SNPs); and deviations from Hardy-Weinberg 
Equilibrium (-391 SNPs). Following QC, the discordant call rate per locus, based on 261 duplicate 
samples, was roughly 5/10,000.  
QC on family data had a similar impact on reducing counts (Table 1), yielding 1,171 families 
for linkage analysis. Of these families, we estimate that 64% were included in smaller, published 
linkage studies. The families were distributed across three diagnostic categories, narrow, broad 
and heterogeneous ASD (or hASD), which were defined according to the distribution of diagnosis 
(see Methods). Linkage analyses were performed for three nested diagnostic groupings, narrow, 
broad and all families; for analyses focusing on one diagnostic group, a reasonable choice is broad 
because a substantial number of families fall in the group and the sensitivity and specificity of this 
diagnostic method are reliable18. 
Prior to linkage analyses, we rebuilt the Affymetrix genetic map by linear interpolation from 
NCBI Build35 and markers of known genetic positions19 to infer genetic locations for all SNPs. 
We then validated the new genetic map by using the linkage data.  
Linkage information, as reported by MERLIN, averaged ≈95% over the genome (minima at 
telomeres, ≥ 71%) because of high coverage of markers across the genome and availability of 
parental genotypes (3% of families have no parental genotypes while 79% have genotypes for both 
parents). Thus the results are also insensitive to SNPs in linkage disequilibrium (see Methods). 
Only for all families does statistical evidence exceed the criterion for suggestive linkage20, at 
11p12-p13 (Fig. 1).  
 
Characterization of copy number variation  
We assessed our samples for CNV content using signal intensities obtained from the SNP arrays. 
Because the distribution of intensity is continuous, whereas copy numbers are discrete, an algorithm 
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is required to infer copy number from signal intensity of a SNP genotype relative to intensity from 
other samples. Initially, to capture as many CNVs as possible, we used two approaches (termed 
batch and plate-by-plate) for intensity comparisons, which yielded a total of 2788 putative CNVs 
from 1109 samples from 715 families (Table 2). To define a more stringent set of CNV calls, we 
examined the raw intensity data from 42 CNV calls that were presumed real based on overlap with 
non-Mendelian genotype errors or by laboratory experimentation. We also assessed samples having 
identical CNVs within the same family, as these could also be considered to be validated calls. 
These analyses identified our plate-by-plate signal intensity comparison to have less background 
and likely contain fewer false-positive data compared with batch (see Methods and ref. 21). 
Therefore, we then scrutinized these intensity files to guide threshold settings to define a 
highly-stringent data set, called ‘filtered,’ containing 624 CNVs from 350 different families 
(Supplementary Table 1). Characteristics of this dataset for affected individuals are presented in 
Figure 2 and discussed below.  
Caveats about these data are: (i) there will be bona fide CNVs in the batch comparison data that 
fail to meet cutoffs in the filtered analysis; (ii) some CNVs could be somatic artifacts, such as cell 
culture-induced rearrangements and aneuploidy; (iii) the mapping resolution of CNV boundaries 
is dependent on local SNP density and is therefore non-uniform; (iv) smaller CNVs will be more 
likely to be missed (Supplementary Figure 1); and (v) balanced rearrangements will not be 
detected. 
Considering solely our highest confidence data, we identified 254 CNVs in 196 ASD cases 
from 173 families (Table 2, Figure 2, Supplementary Tables 2-3). The average and median sizes 
were 3.4Mb and 0.66Mb, respectively, and the majority (66%) were CNV gains, likely owing to a 
greater tolerance in the genome for large gains versus deletions. The observations most relevant to 
ASD disease risk (Supplementary Table 1) included: (i) the identification of 10 families with 
apparently de novo CNVs (in 3 such families the CNV was found in both ASD sibs); (ii) 18 CNVs 
in unrelated cases having genomic locations coincident with published ASD chromosome 
rearrangements; (iii) and 126 CNVs with recurrent (47) or overlapping (79) boundaries suggesting 
they could be non-random events (Supplementary Tables 3-4). We also detected 7 samples from 
three families with known ASD-associated chromosome 15q gains all of which were maternally 
inherited as would be expected (including at least 2 that escaped earlier karyotypic detection). 
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We highlight four CNV discoveries from many other interesting ones, to demonstrate the utility 
and complexity of this data, and also to serve as a prototype of how this new type of genetic 
information can be used in mapping studies. In family AS049, two ASD female sibs were found to 
have apparently identical 300kb CNV losses of chromosome 2p16 not detected in either parent. 
Quantitative-PCR analysis confirmed the microdeletion: microsatellite analysis showed the 
identical maternal chromosomal segment, but no paternal DNA in the sibs, providing a likely 
explanation of paternal gonadal mosaicism. This hemizygous deletion eliminates coding exons 
from the neurexin 1 gene (NRXN1), which represents a functional candidate for ASD based on the 
NRXN1 role in synaptogenesis and its interaction with neuroligins. Rare NRXN1 mutations 
apparently generate risk for ASD and mental retardation16,22,23. Both girls presented with typical 
autism including characteristic developmental delays. Although too young for certainty, one 
appears nonverbal, while her sister had mild language regression. Neither parent had clinically 
important features.  
The second is a recurrent 1.1 Mb CNV gain at chromosome 1q21 found in three families: 
AS048 with one affected male; AS039 with one affected female; and AS007 with two affected 
male sibs and father. It overlaps the same region implicated in mental retardation and other 
anomalies21,24,25.  
In the third example, CNVs of ~933kb were observed at 17p12: as a de novo duplication in an 
affected male-female sib pair in one family (AS068); a maternally-inherited deletion in two 
affected male sibs (AS028); and a paternally-inherited deletion in a ASD female (AS001). This 
interval when duplicated causes Charcot-Marie-Tooth 1A (CMT1A) and when deleted causes 
hereditary neuropathy with liability to pressure palsy26.  This region also overlaps with 
microdeletions seen in some cases of Smith-Magenis Syndrome, which itself has phenotypic 
overlap with ASDs27. Moreover, other microduplications of the same interval have been described 
in cases with mental retardation, speech and language delay, as well as autism and related 
phenotypes28. None of the implied disease-associated CNVs described above were observed in any 
known control sample database, which at the time of the study was comprised of ~500 samples 
from the general population21,29.  
Finally, in two families with duplications of 22q11.2 further complexity is revealed. In family 
AS063, the male proband diagnosed with autism inherited the duplication from his father, but a 
brother with PDD-NOS does not have the duplication. In family AS019, the female sib diagnosed 
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with autism carried the duplication, while an affected brother did not, and the duplication was not 
observed in either parent. Genotyping confirmed the biological parents. FISH analysis confirmed 
duplications in both families and revealed that it was de novo in the second family (data not 
shown.) 
 
Exploration of linkage by subsets of the data  
Linkage analysis identifies regions harboring one or more genetic variants that account for a 
substantial portion of risk in families. Rare de novo or familial CNVs that convey risk to ASD 
could be a source of noise or heterogeneity that decreases sensitivity in linkage analyses. Thus, in 
theory, linkage signals from major loci could be amplified if families with rare CNV risk alleles 
were removed. A sound strategy to evaluate subsets based on known and putative CNVs, however, 
is unclear. Consider our three levels of CNV discovery, namely filtered, plate and batch, which are 
ordered by degree of stringency of evidence required to call a CNV. Moving from filtered to batch 
it is reasonable to assume that the rate of false positives is increasing while the rate of false 
negatives potentially is decreasing. Selecting a single approach a priori favors a certain, unknown 
ratio of false positives to false negatives. This ratio might not be optimal, depending on how much 
of the attributable risk for ASD accrues to CNVs: if CNVs account for a large fraction of the risk, 
the false negative rate is critical; conversely, if CNVs account for a small fraction of the risk, then 
the false positive rate is of greater importance. For this reason, we chose to explore the effects of 
all three levels of CNV discovery. Within each level, we removed families in which at least one 
individual was diagnosed with ASD and also carried at least one putative CNV (Table 3). Using 
the Broad diagnostic group, we recomputed the linkage traces (see Supplementary Fig. 2).  
After removing ‘CNV families’ the data becomes suggestive for linkage in two regions, 
11p12-p13 and 15q23-25.3 (Fig. 3), contrary to results from all broad families. The most 
noteworthy impact occurs for the batch method, which removes the greatest fraction of families. 
When families removed versus retained by the batch method are contrasted for identity-by-descent 
(IBD), heterogeneity is modest except for the 15q25.3 region (Fig. 3).  
The 4:1 ratio of affected males:females, higher reported recurrence risk to siblings of female 
versus male probands8, and the literature30,31 suggest that a useful partition of the ASD families 
would be whether they contained affected females (Female-Containing or FC) or only affected 
males (Male-Only or MO). Thus, we partitioned the families by FC/MO, and recomputed linkage 
 8
traces for each of the three nested groupings of diagnosis (Fig. 4). Congruent with theory32, the FC 
families appear to be more informative for linkage. For instance, for the narrow diagnostic scheme, 
linkage traces cross the suggestive threshold three times, at 5p15.33, 9p24.1 and 11p13-12, 
whereas the traces do not approach this threshold for MO families. Only for the most inclusive 
diagnostic level do linkage traces for MO families cross the suggestive threshold (5q12.3 and 
9q33.3; Fig. 4), but not the same locations as FC families. While the differences between FC and 
MO families in terms of linkage could be due to chance, tests of heterogeneity of IBD reveal 
substantial heterogeneity in 9p, 9q, and 11p, and modest heterogeneity in 5q (Fig. 4). 
Sub-setting the data according to presence of CNVs and according to sex of affected individuals 
appears to generate more informative linkage signals. To test whether combining both approaches 
to form subsets would also be useful, we used the broad diagnostic grouping. Linkage using these 
six subsets (Table 3), FC versus MO by three levels of CNV discovery, provides even more 
support for a risk locus in the vicinity of 11p12-p13 in FC families (Fig. 5). Removing families 
based on the batch method of CNV discovery nominates a 15q23 locus in FC families (Fig. 5), and 
the maximum at 11p12-p13 approaches genome-wide significance, 4.03 versus 4.1. Affected 
individuals in FC families have a slightly elevated rate of CNV detection (2-3%) relative to MO 
families, regardless of CNV-calling method, and the Broad diagnostic group of families has a 
similarly elevated rate of CNV detection relative to hASD; the ‘paired’ rates are not significantly 
different, nor is the interaction of these variables a significant predictor of the presence/absence of 
a detected CNV (unpublished data.) 
Families participating in the AGP studies vary in their ancestry. To evaluate whether linkage 
would be strengthened by analyzing families of relatively homogeneous ancestry, we restricted the 
sample to “European ancestry,” as inferred by principal components33 of SNP genotypes. All 
founders in 995/1168 (85.2%) families were inferred to be of European origin (Supplementary Fig. 
3); inferred ancestry agreed with available self-reports (99.6%). Using this sample, we repeated all 
linkage analyses in Figures 1 and 3-5.  
Exclusion of non-European families generally has only a modest impact on the results (see 
Supplementary Figure 4 for complete results). Linkage traces at chromosome 11p remain 
prominent, especially for FC families, although the linkage region for 11p is much broader. By 
using the batch results to remove “CNV families,” a new region of suggestive linkage emerges, 
namely 4q31.22, which also shows substantial heterogeneity of IBD (p < 0.00006) between 
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retained and removed families. For all MO families, the linkage trace reaches Zlr=3.85 in 9q33.3. 
In addition, previously reported locations for linkage, especially 2q and 7q, gain more support 
from this “European” subset of the data. For example, linkage traces approach genome-wide 
suggestive linkage at 2q31.1 (FC, narrow) and 7q22.2 (MO, broad).  
 
DISCUSSION 
The results obtained from scanning the genomes of the largest cohort of ASD families yet 
assembled delineate a new understanding of the genetic basis for this complex disorder. That risk 
for ASD arises in small part from chromosomal copy number abnormalities (CNAs) was widely 
understood. Yet, for nuclear families containing two or more affected individuals  and 
pre-screened for microscopic CNAs, linkage analyses have implicitly assumed other CNAs would 
play little if any role in the heritable component of ASD. Our CNV results lie in stark contrast with 
this view. Instead we find an appreciable number of families that could be assessed (68/590 or 
11.5%, 36/476 or 7.6%, and 34/350 or 9.7% in the batch, plate, or filter analyses, respectively) 
(Table 2), in which all affected individuals share possibly-detrimental abnormalities. Due to the 
relatively wide and uneven spacing of SNPs and our conservative approach of calling CNVs, we 
have missed many other events of this kind. By contrast, we also find a number of families in 
which only one of the affected relatives has a detected CNA. One possible implication of this 
finding is that in these cases relevant CNV might be a risk factor and not the only causal event. It is 
also possible that closely-related individuals are etiologically heterogeneous. 
With the goal of minimizing heterogeneity that might confound mapping major loci conferring 
risk to ASD, we invested substantial effort to standardize all phases of this multi-centre project, 
including phenotypic assessment, sample ascertainment, genotyping, and analysis. Linkage 
analyses based on a three-level diagnostic scheme produce suggestive evidence for linkage in the 
vicinity of 11p12-p13 (Fig. 1) for one level, all families. Relative to appropriate baseline, evidence 
for linkage at 11p12-p13 is amplified in select subsets of the data: (i) subsets obtained by removing 
families containing one or more affected individuals inferred to carry CNV (Fig. 3); (ii) the set of 
families containing affected females (Fig. 4); and subsets of families based on both sex of affected 
individuals and presence of CNVs (Fig. 5).  For the subset of FC families without affected 
individuals who carry CNVs, the maximum Zlr increases to 4.03. We believe these explorations 
motivate thorough fine-mapping of the 11p12-p13 region. Modest peaks for linkage have been 
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observed previously for this region, but 11p12-p13 has not been a major focus of autism gene 
discovery. 
Several regions have been featured prominently in previous linkage analyses, namely 2q, 7q 
and 17q.  Of these regions, 2q and 7q garner modest linkage support from families of European 
ancestry (Supplementary Fig. 4), whereas the 17q linkage region does not. The largest linkage 
signal on 2q, Zlr = 3.1, occurs for FC families in 2q31.1; the largest signal on 7q, Zlr = 3.1, occurs 
for MO families in 7q22.3. Several explanations are plausible for these results. (i) The previous 
linkages could be false positives. (ii) For linkage studies of complex disorders, statistics for 
identified linkage regions tend to be biased upward relative to that expected from the linked risk 
loci. Because of this bias, combining samples with mixed evidence for linkage and adding new 
families, as done here, will often diminish previously-identified linkage signals. (iii) Studies could 
have collected samples that differ in heritable features tied to risk loci, exaggerating the 
heterogeneity already inherent in ASD. Stochastic variation combined with this heterogeneity 
could overwhelm the linkage signal. 
None of our linkage results can be interpreted as ‘statistically significant’ because we have 
performed numerous analyses of the data. In fact we performed 18 linkage analyses on the full 
sample and 18 using families of European ancestry. Because many of these analyses were 
performed on overlapping subsets of the data, we effectively performed the equivalent of 4-5 
independent genome scans34.   
Our CNV analyses detect a hemizygous deletion of coding exons from NRXN1 for a pair of 
affected siblings. Absent of other information this finding might not be especially meaningful, in 
particular due to the prevalence of CNVs now known to exist in the genome21. However, the 
alteration is a de novo event and Feng et al.23 have reported rare missense variants in NRXN1 in 
ASD subjects not found in over 500 controls. Moreover, NRXN1 interacts with neuroligins, for 
which rare mutations apparently generate risk for ASD and mental retardation14,15. We, therefore, 
evaluated transmissions in our families for four NRXN1 SNPs (rs1363036, rs930752, rs1377238, 
rs2018909). Using the FBAT35 empirical statistic, we tested transmissions under additive and 
dominant models in all families and in the broad subset (dominant and recessive models are 
indistinguishable in this analysis). For all families, biased transmission was significantly noted at 
two loci under the dominant model, for the minor allele of rs1363036 (p = 0.0091) and the major 
allele of rs930752 (p = 0.025)(only rs930752 showed significantly-biased transmission under the 
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additive model, p = 0.014). These SNPs are in modest LD (r2 = 0.048). In the broad subset, results 
strengthen for rs1363036 (dominant, p = 0.0041), but weaken for rs930752 (dominant, p = 0.076; 
additive, p = 0.072). These two SNPs, separated by 88kb, are intronic and are unlikely to convey 
risk directly.  
Accumulating evidence thus implicate neurexins/neuroligins as having a role in risk for ASD. 
For communication of signal between neurons, postsynaptic receptors must oppose 
neurotransmitter release sites on presynaptic axons. Graf et al.36 show that neurexins induce 
postsynaptic differentiation in contacting dendrites, while neuroligins induce presynaptic 
differentiation in glutamatergic axons. The neurexin-neuroligin link is fundamentally-important 
for glutamatergic synaptogenesis (and, apparently, GABAergic synaptogenesis36,37). Moreover, 
aberrant glutamate function is often cited as an important element of risk for ASD38,39, a 
hypothesis compatible with its role as the major excitatory neurotransmitter and critical factor in 
brain development40. Autism-like behaviors and diagnoses of autism are common for individuals 
with either Fragile-X syndrome or tuberous sclerosis, both of which are associated with 
dysregulated glutamate signaling41,42.    
Is oligogenic or “major gene” variation associated with other glutamate-related genes? In 
addition to our results, intriguing evidence for association has been found for the mitochondrial 
aspartate/glutamate carrier SLC25A12 (2q31) and GRIK2 13. Still the protein product of SLC25A12 
is a mitochondrial aspartate-glutamate carrier not known to affect glutamatergic synaptic function. 
Knockout of SLC25A12 in mice impairs myelination of neuronal cells resulting from limitations to 
aspartate delivery, not glutamate43. The protein product of GRIK2, GluR6, is an ionotropic kainate 
receptor that does impact neuronal development. Based on its mapping to 6q16.3, it is not a 
positional candidate according to our results. For FC families, however, linkage results are 
modestly positive (Zlr = 1.9 for all families and families of European ancestry; Zlr ≈ 2.40 for 
families retained using the batch method of CNV-calling). 
When the UCSC Genome Browser is searched with the keyword glutamate, it lists 168 genes. 
Many fall in linkage regions, including 11q13-12 (SLC1A2 and PRRG4), 2q31 (SLC25A12), 
4q28.3 (SLC7A11), 7q21.3 (SLC25A13), 9p24.2 (SLC1A1), 9q34.11 (FGPS), and 15q25.2 
(HOMER2). Of 10 glutamate solute carriers, half fall in the cited linkage regions (keywords = 
glutamate & solute & carrier), but not all are related to glutamatergic synaptic function. SLC1A1 
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and SLC1A2 fall close to linkage peaks, their protein products affect glutamate synapse function 
and brain development, and thus they are excellent targets for positional candidate gene analyses. 
 
METHODS 
Linkage screening set  
A SNP-based genome scan was conducted using the Affymetrix 10K v2 SNP array. Genotyping 
was contracted to the Translational Genomics Research Institute (TGEN). TGEN genotyped DNA 
samples falling into 1496 nominal families, of which 1168 could be used for linkage. 
 
Strategy for linkage analysis   
For linkage analyses we grouped families into three diagnostic classes: narrow, broad and 
heterogeneous ASD (hASD). To qualify for the narrow class, two or more affected individuals had 
to meet criteria for autism on both the ADI-R18 and the ADOS18. For the broad category at least 
one individual had to meet ADI-R criteria for autism and ADOS criteria for autism or ASD. At 
least one other family member required criteria for impairment on the social or communication 
domains of the ADI-R and meet criteria for at least ASD on the ADOS. The hASD families were 
completely independent of the broad and narrow categories, but combined with the broad set to 
analyze linkage in all families. The hASD families consisted largely of (i) families meeting ADI-R 
criteria for ASD or autism18, but absent ADOS evaluation, (ii) multiple individuals per family 
meeting ASD criteria by ADOS and exhibiting impairment on the social or communication 
domains of the ADI-R, but not meeting full criteria for autism on the ADI-R, or (iii) both of the 
above. In addition to diagnostic categories, families were subset by MO/FC status.  
 
Genetic quality control, tag SNP selection and ancestry 
We evaluated three features of data quality, namely degree of missing genotypes (missingness), 
Mendelian errors, and Hardy Weinberg Equilibrium (HW). Individuals (20%) and loci (10%) with 
substantial missing data were not considered for linkage analyses because these features usually 
indicate poor DNA quality and problems with genotype calls, respectively. Likewise loci with 
minor allele frequency MAF < 0.05 were discarded.  
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Mendelian errors were evaluated using PEDCHECK44. Loci showing multiple Mendelian errors – for 
correct family structure – were discarded for linkage testing. To overcome possible problems 
arising due to ancestry we first selected tag SNPs and then evaluated HW with the large sample 
inferred to be of homogeneous European ancestry.  We analyzed linkage disequilibrium (LD) 
using HCLUST45, selecting tag SNPs to represent clusters of others in substantial LD (r2 > 0.8). We 
chose those that were highly correlated with the other SNPs in the cluster; we estimated ancestry 
by using principal component analyses33; and evaluated HW using parental data. Loci were not 
used for analyses if HW was rejected at a p-value < 0.005. Finally we used MERLIN46 to infer likely 
genotyping errors on the basis of apparent genetic recombination. When genotypes were likely to 
be errors (p < 0.01) they were set to missing. 
 
Linkage analysis 
We used the BLUE method47 to estimate allele frequencies. Linkage was estimated from the entire 
set of SNPs using MERLIN46 and the exponential S-all statistic. Linkage was also estimated by 
using MERLIN46 and ALLEGRO48 from tag SNPs. We found virtually no difference in results using 
tag SNPs or all SNPs, with or without using the options in MERLIN to handle LD. We analyzed 
heterogeneity of linkage between strata by using the methods of McQueen49, which test for 
significant differences in shared IBD among affected siblings in families. We computed 
heterogeneity statistics in each region/setting in which a linkage trace crossed the threshold for 
suggestive linkage. 
 
CNV assessment  
CNVs were inferred from Affymetrix 10K array scans using dChip 2006 software (DNA Chip 
Analyzer)50. We have also used other algorithms and the data will be posted at the Autism 
Chromosome Rearrangement Database as it is validated. Initially, 7610 scans were available (this 
number exceeds the 6,709 samples genotyped for linkage since the CNV experiments continued 
after the initial data freeze). We excluded those samples with a genotype call rate less than 92% 
and/or an array percentage outlier of greater than 5% leaving 5997 experiments suitable for CNV 
analyses. For the ‘batch’ analysis we grouped the arrays into 6 cohorts of 1000 samples each. The 
median probe intensities for the arrays varied greatly (<100 to >1000) indicating the need for 
normalization to compare signals. Arrays were normalized at the probe intensity level using 
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invariant set normalization to a baseline array within each group of 1000 experiments50. A signal 
value was then calculated for each SNP using a model-based method and averaged across all 
samples for each SNP to obtain the mean signal of a diploid genome. The observed raw copy 
number was then defined, and copy number inferred for each individual/SNP using a Hidden 
Markov Model50. Since samples were submitted in 96-well plate formats and arrays were 
processed in the same manner, the ‘batch’ analysis contained plate-specific noise apparently 
leading to many false positive CNV calls. In an attempt to increase the signal to noise ratio, we 
analyzed arrays in a 96-well plate specific manner. For example, we excluded 12 plates having less 
than 40 samples after the initial filtering, leaving 5823 scans for the plate analysis. Arrays were 
normalized within each set and copy number calculated in the same manner as was for the ‘batch’ 
analysis. We also excluded those samples with greater than 10 CNVs per sample from all analyses 
to avoid high false-positive calling. Because we had family data, certain CNV could be tentatively 
confirmed by using the family structure and Mendelian errors (although the original CNV calls 
were blind to family status). Using these data as a benchmark the ‘plate’ analysis produced a 
cleaner dataset than the ‘batch’ analysis and was therefore parsed further using a combination of 
more stringent thresholds (less than 5 CNVs per sample) and manual curation of the raw data to 
give a ‘filtered’ dataset. The inferred CNVs for all three datasets were interpreted on several levels. 
We also completed similar analysis for the X-chromosome, but did not include the results since 
only 263 SNPs covered this segment of the genome (40 CNVs were found). Called CNVs were 
also examined for overlap with genomic features including mapped chromosome rearrangement 
breakpoints annotated in the Autism Chromosome Rearrangement Database and polymorphic 
CNVs in the Database of Genomic Variants. For all three analyses, affected individuals and 
families with CNVs that did not have complete overlap with the DGV were removed from linkage 
analysis. 
The raw data from the Affymetrix 10k experiments are posted at the Gene Omnibus Expression 
Database (http://www.ncbi.nlm.nih.gov/geo/) with the Accession #GSE6754. CNV calls are 
released at the Autism Chromosome Rearrangement Database.  
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URLs. Autism Chromosome Rearrangement Database: http://projects.tcag.ca/autism/ 
Database of Genomic Variants: http://projects.tcag.ca/variation/
Gene Omnibus Expression Database: http://www.ncbi.nlm.nih.gov/geo/ 
 
 
Note: Supplementary information is available on the Nature Genetics website. 
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Table 1. Families at each stage of quality control1. 
  Narrow Broad hASD Total 
Diagnostic data ≥ 2 Affected (A) 675 942 554 1496 
Genotypic data ≥ 2 genotyped (G) 675 942 549 1491 
Diagnostic and 
Genotypic data 
≥ 2 A&G 597 829 488 1317 
Edit 1 ≥ 2 A&G 564 787 461 1248 
Edit 2 ≥ 2 A&G 554 772 450 1222 
Edit 3 ≥ 2 A&G 522 731 437 1168 
1Quality control of samples was based on genotypes determined by the Affymetrix10k 
array, which contains 10,112 SNPs. See Supplementary Methods for origin of sample by 
research centre. Edit 1: eliminated pedigrees/samples incompatible with linkage 
assumptions (monozygotic twins and inconsistent nominal/genetic relationships). Edit 2: 
dropped loci missing ≥ 10% of their genotype calls and then individuals missing ≥ 20% of 
their genotype calls (rates determined empirically based on the frequency distribution of 
missing genotypes). Edit 3: removed duplicate individuals/families that contributed DNA 
to more than one centre. Most families were nuclear; after Edit 3, the number of marriages 
per family was 1.26, 1.24 and 1.16 for Narrow, Broad and hASD. 
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Table 2:  Characteristics of CNVs found in multiplex autism families using different stringencies of 
analysis. 
 
                             1Method 
Features  
2Batch 3Plate-by-Plate 4Filtered based 
on thresholds 
Total Samples 
# of CNVs 1967 1286 624 
# of samples 918 685 490 
# of CNVs/sample 2.14 1.88 1.28 
# of families 590 476 350 
5Avg./Median size 4.6/1.8 Mb 3.4/1.2 Mb 3.9/0.6 Mb 
Gain/Loss of CNV 1749/228 1064/232 402/222 
Unaffected Individuals 
# of CNVs 1186 802 370 
# of samples 538 425 292 
# of CNVs/sample 2.20 1.86 1.25 
# of families 419 329 235 
5Avg./Median size 4.7/1.9 3.6/1.3 4.3/0.69 
Gain/Loss of CNV 1054/133 658/143 235/136 
Affected Individuals 
# of CNVs 781 495 254 
# of samples 380 260 196 
# of CNVs/sample 2.06 1.90 1.29 
# of families 322 230 173 
5Avg./Median size 4.6/1.8 3.2/1.2 3.4/0.66 
Gain/Loss of CNVs 685/96 406/89 167/86 
6Inherited CNVs (#Regions) 78 (62) 59 (46) 49 (39) 
7Sibling CNVs (#Regions) 68 (34) 36 (18) 34 (17) 
8De novo CNVs (Siblings) 33 (26) 16 (10) 10 (6) 
9Fam. Recurrent CNVs (#Regions) 28 (14) 16 (8) 14 (7) 
10Recurrent CNVs (#Regions) 209 (66) 135 (43) 47 (18) 
11Overlapping CNVs 422 251 79 
   Non-overlapping CNVs 139 109 128 
12CNVs overlapping with ACRD  68  27  18  
13CNVs overlapping with DGV  20  10  9  
14CNVs validated (in affected) 326 (162) 230 (106) 193 (95) 
15# of families removed for linkage 
analysis modeling 
303 221 166 
1CNV analysis for the arrays was performed using three approaches. After trimming the dataset with the 
first pass cutoffs, arrays were re-normalized and analyzed using a 'batch comparison' (~1000 scans)2 or by 
a 'plate-by-plate' comparison (96 scans)3 to avoid potential plate specific batch effects. In the most 
stringent analysis4 thresholds were set based on validation data (see footnote 14 below) to minimize 
potential for false-positives. We note that while column 4 contains data from the most stringent analysis 
there are some CNVs found exclusively in one or both of the columns 2 and 3 that is indeed real. All data 
can be viewed at the Autism Chromosome Rearrangement Database (ACRD; 
http://projects.tcag.ca/autism/); 
5Range of CNV size: Batch (100bp to 240Mb), Plate-by-Plate (100bp to 134 Mb), Filtered (100bp to 
134Mb); distributions are shown in Supplementary Figure 1; 
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6CNVs in affected individuals that were inherited from either parent;  
7CNVs present in two or more affected siblings that are either de novo or inherited; 
8CNVs in affected individuals that are de novo in origin with the total number of de novo events occurring 
in siblings in brackets; 
9CNVs that are Familial and Recurrent;  
10CNVs gains or CNV losses with the same coordinates found in two or more unrelated families (a 
recurrent CNV gain and CNV loss at the same site is only counted once);  
11Two or more CNV gains or CNV losses with overlapping genomic coordinates (a CNV gain and CNV 
loss combination is not counted); 
12CNVs that overlap with mapped chromosome rearrangement breakpoints annotated in the Autism 
Chromosome Rearrangement Database (ACRD; http://projects.tcag.ca/autism/); 
13CNVs that overlap with other CNVs not known to be associated with disease as catalogued in the 
Database of Genomic Variants (DGV; http://projects.tcag.ca/variation/); We note that some CNVs found 
in the DGV could be predisposing or disease related; 
14Total number of validated CNVs. A CNV was considered validated if it overlapped with Mendelian 
genotype errors, or was confirmed using an independent set of experiments (eg. karyotyping, quantitative 
PCR, array-CGH, Affymetrix 500K Mapping arrays) (see Supplementary Table 4); 
15Number of families belonging to the group of 1168 families passing data cleaning that were removed 
from linkage analysis. Families were only removed if at least one affected individual contained a CNVs 
not found in the Database of Genomic Variants. 
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Table 3. Sample size for families in each level of diagnostic group and partitioned according to 
whether families contained ASD-diagnosed females (FC) or not (MO). 
Diagnostic 
Group1
Families1 Total Filtered Plate Batch
All 528 462 431 406 
MO 334 296 274 259 
 
Narrow 
FC 194 166 157 147 
 
All 739 641 603 567 
MO 464 408 382 359 
 
Broad 
FC 275 233 221 208 
 
All 1181 1031 981 914 
MO 741 653 623 579 
 
All 
FC 440 378 358 335 
1A larger fraction of families tends to be removed from the 
more stringently-diagnosed groups (narrow and broad) and 
from FC families, but neither trend approaches significance 
when the data are fitted to a log-linear model.  
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Figure Captions 
 
Figure 1. Linkage across the genome for all families and ancestries, based on levels of diagnostic 
certainty. Vertical reference lines separate chromosomes, which are ordered. The horizontal 
reference bar is given at a Zlr of 3.18, the threshold for suggestive linkage according to the 
Lander/Kruglyak criterion3, which is roughly accurate in this setting (4.1 is the threshold for 
significant linkage). The suggestive threshold would be expected to be crossed by chance once per 
genome scan. It is crossed once, and the peak falls within 11p12 (Zlr = 3.57 at rs2421826). 
 
Figure 2.  Chromosome ideogram depicting 253 inferred CNVs found in 196 Autism patients 
These CNVs are derived from the highest stringency ‘filtered’ dataset, but many other true CNVs 
will also be found in the other analyses and should be examined further. Characteristics of the 
complete dataset are described in Table 2. Some of the larger changes could represent somatic 
artifacts or missed karyotypic anomalies. All data is also downloadable or viewed in Genome 
Browser format at the Autism Chromosome Rearrangement Database 
(http://projects.tcag.ca/autism/). As additional analyses and validation is performed the data will 
be posted at the same site. 
 
Figure 3. Highlighted linkage results due to removing families in which affected individuals carry 
putative CNV. Results from all families (ignoring CNVs) noted by the cyan line; results from the 
filtered set, the orange line; results from the plate set, red line; and results from the batch set, black 
line. Families all fall in the broad diagnostic category. Complete results are in Supplementary 
Figure 2. For 11p12, the maximum occurs in 11p13 (Zlr = 3.33 at rs2421826). For chromosome 
15, there are two up-crossings: the smaller peak occurs at in 15q23 (Zlr = 3.19 at rs1372828) and 
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the larger in 15q25.3 (Zlr = 3.41 near rs1433452). For families removed versus retained, 
heterogeneity of estimated identity-by-descent was tested in the ± 5 cM linkage region 
surrounding each peak and reported as regional minimum heterogeneity p-value m-p (11p12-p13, 
m-p = 0.074; 15q23, m-p = 0.044; 15q25.3, m-p = 0.004). 
 
Figure 4. Linkage peaks by MO/FC, based on levels of diagnostic certainty. For FC families and 
narrow diagnosis, peaks localize to 5p14.33 (Zlr = 3.41 at rs1968011; m-p = 0.141), 9p24.1 (Zlr = 
3.21 at rs1340513; m-p = 0.0007), and 11p13 (Zlr = 3.77 at rs1358054; m-p = 0.008); for 
FC/Broad, to 9p24.1 (Zlr = 3.59 at rs722628; m-p = 0.006) and 11p13 (Zlr = 3.90 at rs1358054; 
m-p = 0.015); and for FC/All, to 11p12 (Zlr = 3.63 at rs1039205; m-p = 0.078). For all MO 
families, peaks localize to 5q12 (Zlr = 3.26 at rs673743; m-p = 0.019), 9q33.3 (Zlr = 3.30 at 
rs536861; m-p = 0.0005). 
 
Figure 5. The effect on linkage of splitting families into FC and MO families while also removing 
families in which affected individuals putatively carry CNV. For FC families and filtered subset, 
peaks localize to 9p24.1 (Zlr = 3.32 at rs1575284; m-p = 0.105), and 11p12 (Zlr = 3.90 at 
rs1039205; m-p = 0.411); for FC/Plate, to 9p24.1 (Zlr = 3.28 at rs1821892; m-p = 0.295) and 
11p12 (Zlr = 3.48 at rs1039205; m-p = 0.111); and for FC/Batch, to 11p13 (Zlr = 4.03 at 
rs1358054; m-p = 0.014) and 15q23 (Zlr = 3.30 at rs1433452; m-p = 0.044). 
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SUPPLEMENTARY ITEMS  
 
Supplementary Methods. 
 
Supplementary Table 1: List of 624 CNVs in Filtered Analysis. 
 
Supplementary Table 2: List of 254 CNVs in Affected Individuals. 
 
Supplementary Table 3: Breakdown of CNVs in Affected Individuals. 
 
Supplementary Table 4: List of Validated CNVs. 
 
Supplementary Figure 1: Binned size distribution of CNVs in batch (A), plate (B) and filtered (C) 
analyses.  
 
Supplementary Figure 2: Linkage results due to removing families in which affected individuals 
putatively carry CNV.  
Supplementary Figure 3. Principal component plot used to infer ancestry.  
Supplementary Figure 4: Linkage results obtained by analyzing families inferred to be of 
homogeneous European ancestry.  
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